Get the app
US › Healthcare

Atara Biotherapeutics Inc (ATRA)

US · Healthcare · Biotechnology

$9.18-4.87%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$630,000
Revenue YoY
-96.4%
Net profit
$-4.8M
Profit YoY
-302.5%
EPS
$-0.32
EPS estimate
$-0.35
Net margin
-767.3%

EPS came in at -0.32 against a street estimate of -0.35 — a beat of 8.6%.

Key statistics

Market cap
$93.4M
Forward P/E
16.2
P/B
16.14
Book value
$-3.92
EPS (TTM)
$-1.30
52-week high
$19.14
52-week low
$3.92
50-day MA
$9.15
200-day MA
$8.01
Beta
0.22

Analyst view

Analysts rate Atara Biotherapeutics Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $13.67.

Shareholding

Insiders
16.80%
Institutions
57.67%

Largest institutional holders

FundStake
EcoR1 Capital, LLC15.46%
Adage Capital Partners Gp LLC8.47%
Point72 Asset Management, L.P.6.85%
Redmile Group, LLC4.40%
Vanguard Capital Management, LLC2.46%
Mackenzie Investments2.32%
BlackRock Inc0.84%
Geode Capital Management, LLC0.75%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atara Biotherapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.